Laurus Labs and Aspen Pharmacare launch improved triple combination HIV drug

Laurus Labs, a leading integrated pharmaceutical company in India with presence across the globe and partner, Aspen Pharmacare, South Africa’s leading pharmaceutical company, launched a new HIV drug with the triple combination of Tenofovir Disoproxil Fumarate, Lamivudine and Dolutegravir (TLD) in South Africa on November 26, 2018.

Earlier, Aspen Pharma received approvals for the dossier where Aspen Port Elizabeth and Laurus Labs Visakhapatnam are registered as manufacturing facilities, from the South African Health Products Regulatory Authority (SAHPRA).

Named Emdolten, the product provides significant benefits to existing therapies, including countering drug resistance that often develops with older HIV treatments. This once-a-day triple combination tablet is positioned to become a preferred first-line ARV choice in multiple markets. It will be available in 50 mg/300 mg dosages.

As part of the partnership, Aspen launched the product in South Africa for the private market and Laurus Labs will supply the API, from its manufacturing facility located in Jawaharlal Nehru Pharma city, Visakhapatnam. This state-of-the-art facility is approved by USFDA.